Background. Chronic Lymphocytic Leukemia (CLL) represent the most frequent leukemia in adults. Despite recent advances in treatments, CLL remains a deadly incurable disease. This cancer is caracterized by an accumulation of abnormal, apoptosis resistant, B lymphocytes in the blood and lymphoid organs of the patients. CLL progression is highly dependent on complex interactions between tumor cells and their microenvironment. Indeed, CLL cells can modify stromal cells and immune cells to promote their survival and to escape from the immune surveillance system.
Objectives.Our team focuses on the mechanisms leading to leukemia progression, in particular the influence of CLL cells on stromal cells and immune cells located in their microenvironment, with the goal to identify new prognostic markers and therapeutic targets.
Training and research environment. Tumor Stroma Interactions research group is a dynamic and multinational team whose current members originate from France, Belgium, Luxembourg, Spain, Germany, Italy and Argentina. It belongs to the Department of Cancer Research, whose research activities focus on the cellular and molecular mechanisms of tumor progression using a wide range of cutting edge technologies, including genomic, transcriptomic and proteomic analyses, as well as in vitro and in vivo imaging modalities using state-of-the art animal models for cancer research. The post-doctoral researcher will be working on a large FNR CORE-funded project that aims to explore the complex interplay between CLL cells and immune cells in the microenvironment, and will be co-supervised by Dr. E. Moussay (PI) and Dr. J. Paggetti (PI).
Recent related references (open access): Paggetti J, et al. Exosomes released by chronic lymphocytic leukemia cells induce cancer-associated fibroblast formation.Blood 126(9):1106-17.Wierz M, et al. Dual PD1/LAG3 immune checkpoint blockade limits tumor development in a murine model of chronic lymphocytic leukemia. Blood 131(14):1617-1621. (IF:23.8)
More information about the group can be found here : https://tsi.lih.lu
What we offer and conditions
Students will have the opportunity to work in an interactive and international scientific environment, attend conferences by eminent scientists from abroad, and present their own work during lab meetings.
They will receive training in basic biochemistry, molecular and cell biology techniques, such as Western-blotting, real-time PCR, and cell culture, as well as confocal imaging, flow cytometry and in vivo experiments on mouse models.
Mouse experimentation practice and FELASA (or equivalent) diploma would be considered as an asset.
Applicants should be enrolled in a Master program and internship should be a mandatory part of the diploma.
English is mandatory.
Students from abroad can apply for an Erasmus grant.
Présentation de l’entreprise
The Luxembourg Institute of Health (LIH) is a public biomedical research organisation focused on precision health and invested in becoming a leading reference in Europe for the translation of scientific excellence into meaningful benefits for patients. LIH places the patient at the heart of all its activities, driven by a collective obligation towards society to use knowledge and technology arising from research on patient-derived data to have a direct impact on people’s health. Its dedicated teams of multidisciplinary researchers strive for excellence, generating relevant knowledge linked to immune related diseases and cancer. The institute embraces collaborations, disruptive technology and process innovation as unique opportunities to improve the application of diagnostics and therapeutics with the long-term goal of preventing disease. LIH aims to perform research that transcends the boundaries of classical disease definition. Its translational and transversal research strategy, combined with the increasing appreciation of the role of the immune system in determining disease, has led LIH to focus on two priority areas, with inflammation and immunity as the common thread: